ArticleScientific reports2025

A post-marketing surveillance study of dabrafenib and trametinib combination in Japanese patients with unresectable advanced or recurrent BRAF-mutated NSCLC.

Tomoaki Kaizuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.